Caliway to Unveil New Clinical Advancements at 2024 BIO Convention

Caliway Biopharmaceuticals, headquartered in Taiwan, has announced its scheduled participation in the 2024 BIO International Convention, which will take place on Wednesday, June 5th, at 11:45 a.m. PDT. The event will be hosted in Company Presentation Theater 2 at the San Diego Convention Center. The BIO International Convention is renowned for being the leading global gathering in the biotechnology industry, drawing more than 20,000 prominent leaders from about 5,000 esteemed companies worldwide. This four-day, in-person event offers forums on the latest topics, as well as numerous networking and partnering opportunities.

Caliway Biopharmaceuticals will be among the 200+ companies presenting at this prestigious event. The company plans to share recent advancements on its lead pipeline candidate, CBL-514. Phase 2 studies of CBL-514 have shown significant efficacy in several areas. Specifically, the treatment has achieved an average reduction of 312.1 mL in subcutaneous fat. Additionally, CBL-514 has demonstrated potential for treating Dercum's disease and cellulite, marking significant progress in addressing these medical conditions.

Caliway Biopharmaceuticals is a clinical-stage biopharmaceutical firm focused on developing breakthrough small-molecule therapeutics, particularly in the fields of medical aesthetics and inflammatory diseases. The company, listed on the Taiwan Emerging Stock Market (TPEX6919), aims to establish itself as an innovative leader in aesthetic medicine.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!